For example, in non-small-cell lung carcinoma (NSCLC), EGFR tyrosine kinase inhibitors (EGFR-TKI) are used as treatment, but in some cases, EGFR-TKI resistance is detected within one year of drug administration [78]. Here, EGFR is linked to non-small cell lung carcinoma.